Minori Rosales, M.D., Ph.D., serves as Sesen Bio’s Chief Development Officer. Dr. Rosales has played key roles in the development, approval, and commercial launch of oncology and immuno-oncology drugs. She held senior and leadership roles at Eli Lilly, Merck, Medimmune / AstraZeneca, and MacroGenics. Prior to joining the pharmaceutical industry, Dr. Rosales focused on clinical and translational cancer research at several major US institutions, including the University of Pennsylvania, Mount Sinai Medical Center, National Cancer Institute, and New York University. Dr. Rosales earned her M.D. from Yamaguchi University and Ph.D. from Kansai Medical University, and she subsequently trained in surgical oncology in Japan.